NasdaqGS - Nasdaq Real Time Price ? USD Xilio Therapeutics, Inc. (XLO) Follow Compare 0.8092 +0.0302 (+3.88%) At close: October 21 at 4:00 PM EDT 0.8100 +0.00 (+0.10%) After hours: October 21 at 7:28 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHAN GlobeNewswire ? 17 days ago XLO +3.88% Xilio Therapeutics Announces Inducement Grants Under?Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2024, the Compensation Committee of the Board of Directors granted non-qualified stock options to purchase an aggregate of 101,000 shares of its common stock to three new employees under Xilio Therapeutics’ 2022 Inducement Stock GlobeNewswire ? 19 days ago XLO +3.88% Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:00 am EDT. A live webcast can be accessed under “Eve GlobeNewswire ? last month XLO +3.88% Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) Initiated enrollment in Phase 1B monotherapy dose expansion for XTX301, a tumor-activated IL-12, in patients with advanced solid tumors; Phase 1A monotherapy dose escalation ongoing with no dose-limiting toxicities observed to date Expect to report clinical data for XTX101 and XTX301 in the fourth GlobeNewswire ? 2 months ago XLO +3.88% Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth? Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? 3 months ago XLO +3.88% Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company’s board of directors. “On behalf of the entire board of directors, it is a privilege to welcome Aoife and James, both well-recognized biotech industry veterans, to the board o GlobeNewswire ? 4 months ago XLO +3.88% Gilead and Cartography enter deal to develop cancer therapies Cartography is entitled to receive $20m upfront, followed by additional near-term preclinical milestone payments. Pharmaceutical Technology ? 4 months ago GILD XLO +3.88% Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 Advancing research-stage pipeline of tumor-activated bispecifics and immune cell engagers Anticipate cash runway into the second quarter of 2025 WALTHAM, Mass., May 14, 2024 ( GlobeNewswire ? 5 months ago XLO +3.88% Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors. Zacks ? 6 months ago XLO +3.88% GILD FGEN Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and commercialize XTX301, a tumor-activated IL-12 Anticipates cash runway into the second quarter of 2025 WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnolo GlobeNewswire ? 6 months ago XLO +3.88% Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company’s promising research platform for tumor-activated bispecific and cell engager moleculesReports additional Phase 2 data for XTX202, a tumor-activated, beta-gamma biased IL-2, supporting potential as combination therapy; plans to discontinue monotherapy development and evaluate GlobeNewswire ? 6 months ago XLO +3.88% Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program FOSTER CITY, Calif. & WALTHAM, Mass., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301. Business Wire ? 6 months ago XLO +3.88% GILD Gilead bets on Xilio cancer drug as biotech restructures Xilio will get just over $40 million from Gilead in return for a license to its experimental IL-12 immunotherapy. The biotech is also discontinuing other work and laying off staff. BioPharma Dive ? 6 months ago XLO +3.88% GILD Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion during the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 am EST. A live webcast can be acces GlobeNewswire ? 7 months ago XLO +3.88% Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST. A live webcast can be accessed under “Events & Pres GlobeNewswire ? 8 months ago XLO +3.88% Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date Initiated patient dosing in Phase 1/2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab Based on recently accelerated enrollment, now plan to report Phase 2 trial data for XTX202, a tumor-activated, beta-gamma biased IL-2, at the 4.0 mg/kg dose by end of first qua GlobeNewswire ? 9 months ago XLO +3.88% Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose (RP2D) continues to demonstrate minimal treatment-related adverse events, consistent with tumor-activated molecule design, and a 33% disease control rate across a range of late-line and IO refractory advanced solid tumors Previously reported confirmed partial response with XTX101 monotherapy GlobeNewswire ? 10 months ago XLO +3.88% Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results Demonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and XTX202, a tumor-activated, beta-gamma IL-2 On track to activate trial sites for XTX101 dose escalation in combination with atezolizumab under clinical collaboration with Roche in the fourth quarter of 2023 Reported initial Phase 1/2 data for XTX202, including a 50% disease control rate at higher doses (≥2.8 mg/kg), and plans to evaluate XTX202 as mono GlobeNewswire ? 11 months ago XLO +3.88% Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at doses up to 4 mg/kg administered once every three weeks in outpatient setting, with no reported signs or symptoms of vascular leak syndrome Two patients continuing treatment for more than 1 year, demonstrating XTX202 was w GlobeNewswire ? 11 months ago XLO +3.88% Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered GlobeNewswire ? 11 months ago XLO +3.88% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return XLO S&P 500 YTD +47.13% +22.73% 1-Year -58.29% +38.58% 3-Year -94.61% +28.80%
